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ABSTRACT Combination antiretroviral therapy (cART) effectively suppresses HIV-1
replication and enables HIV-infected individuals to live long, productive lives. How-
ever, the persistence of HIV-1 reservoirs of both T and myeloid cells with latent or
low-replicating HIV-1 in patients under cART makes HIV-1 infection an incurable dis-
ease. Recent studies have focused on the development of strategies to activate and
purge these reservoirs. Bromodomain and extraterminal domain proteins (BETs) are
epigenetic readers involved in modulating gene expression. Several bromodomain
inhibitors (BETi) are reported to activate viral transcription in vitro in HIV-1 latency
cell lines in a P-TEFb (CDK9/cyclin T1)-dependent manner. Little is known about BETi
efficacy in activating HIV-1 reservoir cells under cART in vivo. Here we report that a
BETi (I-BET151) efficiently activated HIV-1 reservoirs under effective cART in human-
ized mice in vivo. Interestingly, I-BET151 during suppressive cART in vivo activated
HIV-1 gene expression only in monocytic cells and not in CD4 T cells. We further
demonstrate that BETi preferentially enhanced HIV-1 gene expression in monocytic
cells rather than in T cells and that whereas CDK9 was involved in activating HIV-1
by I-BET151 in both monocytic and T cells, CDK2 enhanced HIV-1 transcription in
monocytic cells but inhibited it in T cells. Our findings reveal a role for CDK2 in dif-
ferential modulation of HIV-1 gene expression in myeloid cells and in T cells and
provide a novel strategy to reactivate monocytic reservoirs with BETi during cART.
IMPORTANCE Bromodomain inhibitors have been reported to activate HIV-1 transcrip-
tion in vitro, but their effect on activation of HIV-1 reservoirs during cART in vivo is un-
clear. We found that BETi (I-BET151) treatment reactivated HIV-1 gene expression in hu-
manized mice during suppressive cART. Interestingly, I-BET151 preferentially reactivated
HIV-1 gene expression in monocytic cells, but not in CD4 T cells, in cART-treated mice.
Furthermore, I-BET151 significantly increased HIV-1 transcription in monocytic cells, but
not in HIV-1-infected CD4 T cells, via CDK2-dependent mechanisms. Our findings sug-
gest that BETi can preferentially activate monocytic HIV-1 reservoir cells and that a com-
bination of reservoir activation agents targeting different cell types and pathways is
needed to achieve reactivation of different HIV-1 reservoir cells during cART.
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The global implementation of combination antiretroviral therapy (cART) has trans-formed human immunodeficiency virus type 1 (HIV-1) infection from a fatal disease
into a manageable chronic illness and has successfully blunted the HIV pandemic (1–3).
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HIV-1 replication can be suppressed and maintained at a level below the detection
limits by current cART regimens. However, cART is still unable to cure HIV-1 infection.
Drug resistance, serious non-AIDS events, and financial and societal issues associated
with lifelong cART highlight the urgent need to find a cure for the disease (4–7). Recent
efforts thus have focused on interventions that can yield a drug-free remission of HIV-1
replication or even eradication of replication-competent HIV-1 proviruses in patients.
The major obstacle to eradicating HIV-1 is the persistence of HIV-1 reservoirs that are
able to produce infectious viral particles and result in viral relapse off cART (8–11).
Although resting CD4 T cells with latent HIV-1 infection are the best-characterized
source of HIV-1 reservoirs during cART in patients, myeloid cells with low replicating
(low HIV-1 mRNA) have also been detected in cART-treated patients (12, 13), in simian
immunodeficiency virus (SIV)-infected cART-treated nonhuman primates (NHP) (14, 15),
and in HIV-infected cART-treated humanized mice (16, 17). The molecular mechanisms
associated with the maintenance and reactivation of HIV latency have been extensively
investigated, including transcriptional interference, deleterious mutations in the viral
genome, low levels of transcriptional activators, inadequate Tat activity, and epigenetic
repression (18, 19). Multiple mechanisms are most likely involved in HIV-1 reservoir
persistence, and the relative importance of these mechanisms in different cell types
remains to be determined.
Macrophages are susceptible to HIV-1 infection in human and animal models
(20–23), and HIV-1 could be recovered from the circulating monocytes in patients
treated with cART (24, 25). In addition, HIV-1 is able to infect and replicate in brain
microglia cells that could persist despite cART (26, 27). Recent reports have demon-
strated that humanized mice with myeloid cells only allow HIV-1 persistent infection in
macrophages during cART in vivo (23), and integrated HIV-1 DNA can be detected in the
bone marrow and spleen macrophages in humanized mice during cART (28). These
findings highlight that monocytes or macrophages, as well as resting CD4 T cells, are
of great clinical importance in terms of HIV-1 reservoir persistence and HIV-1 cure.
It is known that bromodomain-containing protein 4 (BRD4) competes with P-TEFb
and disrupts the interaction between Tat and P-TEFb, thus abrogating the ability of Tat
to transactivate HIV-1 transcription (29–31). Given the important role of P-TEFb in
regulating HIV gene expression, a number of bromodomain inhibitors (BETi) have been
tested to activate HIV-1 gene expression in latent models of primary CD4 T cells,
lymphocytic T cell lines, and monocytic cell lines (32, 33). However, little is known about
the therapeutic potential of BETi in activating viral replication in HIV-1 reservoirs during
cART in vivo.
In this study, we tested how a bromodomain inhibitor (I-BET151) affected viral
replication in HIV-1 reservoir cells in vivo during suppressive antiretroviral therapy in
humanized mice. Our results demonstrate that I-BET151 treatment leads to reactivation
of HIV-1 gene expression preferentially in monocytic cells during cART in vivo. We
further demonstrate that BETi preferentially enhanced HIV-1 gene expression in mono-
cytic cells rather than in T cells and that CDK2 enhanced HIV-1 transcription in
monocytic cells but inhibited it in T cells.
(This article was submitted to an online preprint archive [34].)
RESULTS
Bromodomain inhibitor I-BET151 activates HIV-1 replication under suppressive 
cART in vivo. Bromodomain inhibitors have been shown to activate HIV-1 gene 
expression in different cell systems in vitro with latent or chronic HIV-1 infection 
(30–33). In order to investigate the effect of BETi on viral reservoirs in vivo, we  
characterized the pharmacokinetic (PK) and pharmacodynamic (PD) properties of 
I-BET151 in mice. We showed that at a dose of 18 mg/kg of body weight, the concen-
tration of I-BET151 was maintained at a relative steady level (10 times above the 50%
effective concentration [EC50] for HIV-1 activation) for at least 8 h in blood after initial 
administration through gavage (Fig. 1A and B). These data indicate that the dose was 
sufficient to activate HIV-1 gene expression in mice in vivo. Thus, we treated humanized
FIG 1 I-BET151 treatment activates HIV-1 reservoirs under suppressive cART in vivo. (A) Pharmacokinetics/pharmacodynamics of I-BET151
in NSG mice. NSG mice were treated with 18 mg/kg of I-BET151 through gavage, and drug concentration in blood was measured by
high-performance liquid chromatography (HPLC). (B to D) Humanized mice were infected with HIVJR-CSF. cART was initiated at 13 wpi. BETi
treatment was initiated at 21 wpi by daily gavage (18 mg/kg) until termination at 22.3 wpi. (B) HIV plasma load. (C) Relative cell-associated
viral RNA levels in human cells of lymphoid tissues (spleen [SP], bone marrow [BM], liver [LV], and lung [LU]), normalized to human CD4
mRNA level. (D) Cell-associated HIV-1 DNA copies in human cells in different tissues (spleen, bone marrow, liver, and lung) were measured
by real-time PCR. Bars in dot graphs indicate mean values. *, P 0.05.
mice with I-BET151 (18 mg/kg) once every day for activation of HIV-1 gene expression 
in the following experiments. To assess the activity of I-BET151 in activating HIV-1 
reservoir cells, HIV-1-infected humanized mice were treated with I-BET151 for 9 days 
starting at 21 weeks postinfection (wpi) by daily gavage, after viremia was completely 
suppressed for 4 weeks by cART. Consistent with its activity in vitro, HIV-1 viremia 
rebound was detected on day 9 (22.3 wpi) after I-BET151 initiation (Fig. 1B). To identify 
the putative HIV-1 reservoir cells responding to I-BET151 treatment, animals were 
terminated immediately after viremia rebound was detected. Leukocytes from spleens 
and bone marrow, and tissues from liver and lung, were harvested and subjected to 
detection of cell-associated HIV-1 RNA and DNA by TaqMan real-time PCR. We dem-
onstrated that blood viral load rebound was accompanied by a higher level of cell-
associated HIV-1 RNA in human cells in different organs or tissues (Fig. 1C). However, 
a similar level of HIV-1 DNA in human cells was detected in tissues upon the activation 
of viral replication after BETi treatment (Fig. 1D), indicating no new virus spreading 
infection.
We observed no significant toxic effect of I-BET151 on the gross health of the treated 
mice. We found no effect on human leukocytes in treated and nontreated animals, 
including total numbers of human CD45 cells (Fig. 2A), CD3 T cells (Fig. 2B), dendritic 
cells (Fig. 2C), or monocytes (Fig. 2D), in the spleen or bone marrow. In addition, relative 
CD4 and CD8 T cells were not affected by I-BET151 (Fig. 2E and F). These data 
indicate no significant cytotoxicity of BETi treatment in vivo. We conclude that I-BET151 
treatment reactivates HIV-1 gene expression during effective cART, without significant 
cytotoxicity to human myeloid and lymphoid cells in vivo.
I-BET151 specifically activates HIV-1 replication in monocytes in vivo. In order 
to define the HIV-1 reservoir cells that were activated by BETi, we investigated what cell 
types were activated to express HIV-1 p24 proteins by I-BET151 treatment in vivo at 22.3 
wpi (Fig. 1A). Surprisingly, we did not observe any CD4 T cells with detectable p24
FIG 2 I-BET151 treatment shows no significant cytotoxicity in humanized mice. Animals were treated as described for Fig. 1, and cells
harvested from spleen or bone marrow were counted and analyzed by flow cytometry. (A) Human CD45 leukocyte numbers. (B) Human
CD3 T cell numbers. (C) CD3 CD14 CD11c dendritic cell numbers. (D) CD3 CD11c CD14 monocyte numbers. (E) Plots show
percentages of CD4 T cells and CD8 T cells in the spleen and bone marrow. (F) Summary data show percentages of CD4 T cells and
CD8 T cells in CD3 cells in spleen and bone marrow. Bars in dot graphs indicate mean values.
(Fig. 3A and B). In contrast, a significant percentage of human monocytes became p24 
positive after I-BET151 treatment (Fig. 3C and D). We did not detect any significant p24 
expression in other populations, including CD3 CD14 CD11c cells (dendritic cells) 
and CD3 CD11c CD4 CD123 cells (pDCs) (data not shown). To confirm this finding, 
we performed immunofluorescence costaining of HIV-1 p24 and human CD3 or CD14 
on spleen tissue sections. Consistently, we found that p24 staining was colocalized only 
with CD14 cells in the I-BET151 group and not with CD3 T cells. In comparison, no 
p24-positive cells were detected in cART-only mice, indicating an effective suppression 
of HIV-1 replication by cART (Fig. 3E). Although monocyte numbers in the spleen were 
not altered by I-BET151 (Fig. 2D), the p24 monocyte number was significantly in-
creased by I-BET151 treatment (Fig. 3F). Similar findings were also obtained in the bone 
marrow, as I-BET151 treatment activated HIV replication only in monocytes and not 
CD4 T cells (Fig. 4A to D). In a separate experiment with sustained cART, the elevated 
viral load induced by I-BET151 treatment could be inhibited again when I-BET151 was 
stopped (data not shown), indicating that the observed rebound of viral RNA produc-
tion was not due to the emergence of drug-resistant mutant viruses.
I-BET151 activates HIV-1 gene expression more efficiently in MDMs than in 
resting CD4 T cells. It has been reported that BETi activates HIV-1 gene transcription 
in latent models of both T cells and monocytic cells in vitro (32, 33). To confirm our 
finding, we transduced either resting CD4 T cells or monocyte-derived macrophages 
(MDMs) with vesicular stomatitis virus G protein (VSV-G) HIV Duo-Fluo reporter virus. 
This reporter virus encodes a long terminal repeat (LTR)-driven enhanced green fluo-
rescent protein (eGFP) marker (productive infection) and the mCherry marker driven by 
an EF1 promoter (35, 36). After transduction, cells were cultured for 24 h before 
I-BET151 treatment. GFP expression was determined at 72 h for CD4 T cells and 36 h 
for MDMs after culture with I-BET151. We used suberoylanilide hydroxamic acid (SAHA),
FIG 3 I-BET151 treatment preferentially activates HIV replication in monocytic cells under suppressive cART in spleens. Humanized mice were
treated as described for Fig. 1, and splenocytes were harvested for flow cytometry analysis. Fixed spleen tissues were also analyzed by
immunofluorescent staining. (A) Histograms show percentages of HIV gag p24 CD4 T (CD3 CD8) cells in spleens. (B) Summarized
percentages of p24 CD4 T cells in spleens. (C) Histograms show percentages of p24 monocytic cells (CD3 CD11c CD14) in spleens. (D)
Summarized percentages of p24 monocytic cells in spleens. (E) Immunofluorescence costaining of CD3 (green)/Gag p24 (red) (upper row) or
CD14 (green)/Gag p24 (red) (lower row) in spleens. (F) HIV Gag p24 monocyte numbers in spleens. Bars in dot graphs indicate mean values.
a histone deacetylase (HDAC) inhibitor reported to activate HIV LTR transcription in 
both cell lines and primary CD4 T cells (37–39), as a positive control. The results show 
that I-BET151 was unable to significantly enhance HIV-1 transcription in resting CD4 
T cells (Fig. 5A and B). In contrast, HIV-1 transcription in MDMs was significantly 
increased by I-BET151 (Fig. 5C to E).
I-BET151 activates HIV-1 gene expression in monocytic cells via CDK2- and CDK9-
dependent mechanisms. As previously reported, inhibition of either cyclin-dependent 
kinase 2 (CDK2) or CDK9 suppresses HIV-1 transcription or replication (40–45), and 
bromodomain inhibitor-induced reactivation of HIV-1 latency is dependent on CDK9 
(30, 31). In CDK2 knockdown macrophage-like cells derived from pluripotent stem cells, 
HIV-1 replication is significantly reduced (46). To study the mechanism of I-BET151-
enhanced HIV-1 transcription in monocytic cells and CD4 T cells, we first established 
cell lines transduced with a reporter HIV-1 genome expressing luciferase under the 
control of the HIV-1 LTR using either U937 myeloid (U937-luc) or Jurkat T (Jurkat-luc) 
cells. We treated cells with I-BET151 in the presence of either the highly specific and 
potent CDK2 inhibitor K03861 (47) or the CDK9 inhibitor LDC000067. In U937-luc cells, 
either the CDK2 or CDK9 inhibitor alone downregulated HIV-1 transcription relative to 
that in mock-treated cells. In addition, I-BET151 enhancement of HIV-1 transcription 
was abolished by either CDK2 (1 M) or CDK9 (25 M) inhibitor (Fig. 6A). Interestingly, 
the CDK9 inhibitor, but not the CDK2 inhibitor, suppressed I-BET151-enhanced HIV-1 
gene expression in Jurkat-luc cells (Fig. 6B). In fact, the CDK2 inhibitor appeared to 
slightly enhance HIV-1 gene expression in the absence or presence of I-BET151. These
FIG 4 I-BET151 preferentially activates HIV replication in monocytes in the bone marrow of humanized mice on cART.
Humanized mice were treated as described for Fig. 1, and bone marrow cells were analyzed. (A) Histograms show
percentages of HIV Gag p24 CD4 T cells (CD3 CD8). (B) Summarized percentages of p24 CD4 T cells. (C)
Histograms show percentages of HIV Gag p24 monocytes (CD3 CD11c CD14). (D) Summarized percentages of
p24 monocytes. (E) p24 monocyte numbers in the bone marrow (BM). Bars in dot graphs indicate mean values.
results suggest that the different efficacies of I-BET151 in activating HIV-1 transcription 
in monocytic cells and CD4 T cells may be attributed to cell-intrinsic differences in the 
regulation of HIV-1 transcription by CDK2.
DISCUSSION
Despite the importance of HIV-1 reservoirs in resting CD4 T cells, it is impossible to 
achieve a cure without considering reservoir cells like macrophages in brain tissues (48, 
49). The existence of HIV-1 reservoirs in macrophages in vivo is strongly supported by 
Honeycutt et al. (23), who demonstrated that HIV-1 replication can be sustained in 
macrophages in a humanized mice model without T cells. Consistently, our study 
demonstrates that monocytes or macrophages are HIV-1 reservoir cells during suppres-
sive cART in humanized mice. Importantly, bromodomain inhibitors could be used to 
preferentially activate this particular myeloid cell HIV-1 reservoir in vivo.
In this study, no reduction of cell-associated HIV-1 DNA in human cells solely by 
I-BET151 was observed after 9 days’ treatment. We speculate that the poor elimination 
of HIV-1 reservoir induced by I-BET151 in vivo is due to two reasons. First, macrophages 
are more resistant to HIV-1 infection-induced cytopathic effect than are CD4 T cells 
(50, 51). As I-BET151 effectively reactivates HIV-1 replication only in monocytic cells in 
vivo, it is likely that the cells are simply not dying while producing viruses. Second, the 
immune system might be still defective or exhausted due to chronic HIV-1 infection 
though viral replication being suppressed by cART, as recently reported (16, 52). A 
recent study showed that cytotoxic T lymphocyte (CTL)-mediated cytolytic killing rate 
can be significantly faster than the HIV-1 lytic infection death rate in vivo (53). Given the 
above-mentioned possibilities, bromodomain inhibitor treatment should be combined
with other therapies that can either kill HIV-1-positive cells directly (e.g., immunotoxin)
or enhance the host immune response to HIV-1 infection (16) to synergistically purge
HIV-1 reservoir cells.
It is known that HIV-1 reservoir cells can exist in two different statuses in vivo. One
FIG 5 I-BET151 treatment activates HIV-1 transcription in MDMs but not in resting CD4 T cells in vitro. CD25
resting CD4 T cells and MDMs were transduced with VSV Duo-Fluo I virus and cultured for 24 h before I-BET151
treatment. Cells were analyzed for GFP expression at 72 h (CD4 T cells) or 36 h (MDMs) after I-BET151 treatment,
(A) Plots show GFP cells in CD4 T cells. (B) Summarized percentage of GFP cells in CD4 T cells. (C) MDMs
confluence (upper row) and GFP frequency (lower row) observed under a fluorescence microscope. (D) Plots show
GFP expression in MDMs. (E) Summarized percentage of GFP cells in MDMs. Error bars indicate SD.
FIG 6 CDK2 activation by I-BET151 enhances HIV-1 transcription in monocytic cells but inhibits it in T cells. 
U937 cells and Jurkat cells were transduced with VSV HIV-luc reporter virus. After expansion for 6 days, cells 
were treated with a CDK2 or CDK9 inhibitor with or without I-BET151 treatment in triplicates. At 48 h after 
I-BET151 treatment, luciferase activity in cells was measured. (A) Luciferase activity in U937 cells after CDK2 or 
CDK9 inhibitor treatment with or without I-BET151 at 48 h after treatment. (B) Luciferase activity in Jurkat cells 
after CDK2 or CDK9 inhibitor treatment with or without I-BET151 at 48 h. Error bars indicate SD.
is harboring latent replication-competent proviruses expressing few to no viral genes. 
The long-lived resting memory CD4 T cells are the putative latent reservoir cells most 
extensively studied to date (54–56). Some HIV-1 reservoir cells still support low levels 
of HIV-1 replication, due to either sanctuary sites that have low accessibility to cART or 
the cell types that are less responsive to antiretroviral drugs, such as monocytes or 
macrophages (57–59). A recent report has documented the existence of lymphoid 
tissue sanctuary sites for harboring low levels of viral replication in patients with 
undetectable viremia (60). In addition, brain resident macrophages or microglial cells 
have been implicated in maintaining HIV-1 persistent infection (48, 49). In our study, we 
could not distinguish if the increased level of HIV-1 replication in monocytic cells was 
due to activation of latent HIV provirus or further enhancement of residual low levels 
of viral replication. However, it is clear that BETi did not increase the number of 
HIV-infected cells, indicating activation of HIV-1 gene expression in preinfected target 
cells during cART. It is of interest to isolate these myeloid HIV-1 reservoir cells and 
investigate the status of their proviral DNA (latent or low replicating) and the host 
signaling pathways that may contribute to their persistence. Moreover, higher dosages 
should be tested in future studies for possible cytotoxicity effects in mice, NHP, and 
human patients. Our findings shed light on the development of strategies to specifically 
activate these myeloid HIV-1 reservoirs during cART.
In the absence of HIV-1 transactivator Tat, RNAPII pauses after transcription of the 
TAR sequence. P-TEFb consists of cyclin T1 and CDK9 and converts promoter-proximally 
paused RNA polymerase II (RNAPII) complexes into efficient elongating complexes (29). 
Tat recruits P-TEFb via CycT1 to TAR, allowing CDK9 to phosphorylate the C-terminal 
domain (CTD) of RNAPII to continue viral gene transcription (61). It has been reported 
that CDK2 can phosphorylate either CDK9 or Tat and thereby contributes to enhanced 
HIV-1 transcription (62, 63). These findings indicate both CDK9 and CDK2 are involved 
in the regulation of HIV-1 transcription. We indeed confirmed that I-BET151 enhanced 
HIV-1 gene expression in monocytic cells via mechanisms that depended on both CDK9 
and CDK2. In the Jurkat T cell line, we observed that CDK9 inhibitor, but not CDK2 
inhibitor, suppressed I-BET151 enhanced HIV-1 gene expression in Jurkat-luc cells. 
Interestingly, the CDK2 inhibitor appeared to slightly enhance HIV-1 gene expression in 
the absence or presence of I-BET151. Modulation of HIV-1 transcription by interactions 
between CDK2, CDK9, and P-TEFb is complex (62, 64) and may contribute to the 
different efficacies of I-BET151 in activating HIV-1 transcription in monocytic cells and 
CD4 T cells. CDK2 expression is reported to be relatively low in resting CD4 T 
lymphocytes (65), although other host and viral factors may be involved. It will be 
interesting to elucidate the exact mechanisms of the differential response of HIV-1 
reactivation in myeloid cells and in T cells in future studies.
Although the mechanisms contributing to HIV-1 transcription quiescence or latency 
have been investigated extensively, we still do not fully understand the relative 
importance of each mechanism in different cell types. As we have reported previously, 
depletion of regulatory T cells during cART in humanized mice leads to reactivation of 
HIV-1 replication predominantly in memory CD4 T cells but not in monocytic cells in 
humanized mice (17). In a recent report, it was shown that BET inhibitors reactivate 
latent HIV-1 in cells with integration sites distinct from those activated by HDAC 
inhibitors and PKC pathway agonists (66). It is thus possible that BET inhibitors activate 
HIV-1 differently in monocytic cells due to distinct signaling pathways and integration 
sites. This report is based on findings from the CCR5-tropic HIV-1 isolate HIVJR-CSF, which 
infects both myeloid cells and T cells in humanized mice in vivo (Fig. 3 and 4) (17). Other 
HIV-1 isolates with different coreceptor usage and macrophage tropism should be 
tested in order to fully understand the therapeutic effect of bromodomain inhibitors as 
well as other latency-reversing agents in activating latent HIV-1 in myeloid and T cells. 
To facilitate HIV-1 cure therapy, it is of particular importance to identify all possible 
HIV-1 reservoir cells in lymphoid organs and other tissues in vivo and to understand 
how HIV-1 maintains its low replication or latency in different cell types for future drug 
design and therapeutic development.
MATERIALS AND METHODS
Construction of humanized mice. Human fetal liver tissues were obtained from elective or 
medically indicated termination of pregnancy through a nonprofit intermediary working with outpatient 
clinics (Advanced Bioscience Resources). Approval for animal work was obtained from University of North 
Carolina (UNC) Institutional Animal Care and Use Committee (IACUC). We constructed hu-NRG mice as 
previously reported (17, 67–71).
HIV-1 infection of humanized mice. Humanized mice were infected by intravenous (i.v.) injection 
with HIV-1JR-CSF stocks (10 ng of p24/mouse in 50 l) or with mock stocks in control mice.
cART regimens in hu-NRG HSC mice. Individual tablets of tenofovir-emtricitabine (Truvada; Gilead 
Sciences) or raltegravir (Merck) were crushed into fine powder and manufactured as 5BXL by TestDiet 
based on previously published methods (16, 72).
Quantification of HIV load in plasma. Peripheral blood was collected with EDTA as an antico-
agulant at designated time points after HIV infection. Plasma was prepared by centrifugation and 
stored at 80°C until assay. Viral RNA was isolated from the plasma. HIV load was measured by 
quantitative reverse transcription-PCR (qRT-PCR) as described previously (detection limit is 400 
copies/ml) (16, 17, 68).
Cell-associated HIV-1 RNA. Total RNA was extracted from cells or tissues using an RNeasy plus 
minikit (Qiagen). HIV-1 RNA was detected as previously described (16, 17, 68). HIV-1 gag RNA expression 
was normalized to human CD4 or CD14 mRNA level, and relative HIV-1 gene expression levels were 
calculated according to the threshold cycle (2ΔΔCT) (16, 73).
Cell-associated HIV-1 DNA. Total nucleic acid was extracted from cells or tissues using a DNeasy 
minikit (Qiagen). HIV-1 DNA was quantified by real-time PCR. Genomic DNA of ACH2, which contains one 
copy of the HIV genome in each cell, was serially diluted in mouse leukocyte DNA to generate a standard 
curve (16).
Flow cytometry. For HIV-1 Gag p24 staining, cells were stained with surface markers first and 
then permeabilized with Cytofix/Cytoperm buffer (BD Bioscience; catalog number 554714), followed 
by intracellular staining. Phycoerythrin (PE)-conjugated anti-human CD11c (clone 3.9, catalog num-
ber 301606), PE/Cy5-conjugated anti-human CD4 (clone RP4-T4, catalog number 300510), PE/Cy7-
conjugated antihuman CD3 (clone HIT3a, catalog number 300316), Pacific blue-conjugated anti-
human CD14 (clone HCD14, catalog number 325616), and allophycocyanin (APC)/Cy7-conjugated 
anti-human CD45 (clone H130, catalog number 304014) were purchased from Biolegend; Pacific 
orange-conjugated anti-mouse CD45 (clone HI30, catalog number MHCD4530), PE-TR-conjugated 
CD8 (clone 3B5, catalog number MHCD0817), and a LIVE/DEAD fixable aqua dead cell stain kit 
(catalog number L34957) were purchased from Invitrogen. Fluorescein isothiocyanate (FITC)-
conjugated anti-HIV p24 (clone FH190-1-1, catalog number 6604665) was purchased from Beckman 
Coulter. Flow cytometry was performed using either CyAn ADP (Dako) or BD LSRFortessa (BD 
Biosciences), analyzed by Summit 4.3 (Beckman Coulter) or FlowJo 10 (FLOWJO, LLC) accordingly.
Immunofluorescence staining of spleens. Mouse spleens were harvested, fixed with 10% formalin 
(Fisher, Fair Lawn, NJ), embedded in paraffin, and cut into 5-m tissue sections. Antigen retrieval was 
performed by incubation in Diva Decloacker (Biocare Medical, Concord, CA) for 30 min at 95°C, followed 
by slow cooling down for 1 h. The tissue section was blocked with Background Sniper (Biocare Medical). 
The sections were then stained with the following primary antibodies: rabbit monoclonal anti-human 
CD3 (Life Span Bio Sciences, Seattle, WA; 1:100 dilution) or rabbit monoclonal anti-human CD14 (Abcam; 
1:500 dilution) or mouse monoclonal anti-HIV-1 p24 (Dako; 1:5 dilution) diluted in blocking buffer 
(phosphate-buffered saline [PBS], 0.05% Tween 20, 5% goat serum). They were then stained with the 
following secondary antibodies: Alexa Fluor 594 donkey anti-mouse IgG (Life Technologies, Eugene, OR) 
and Alexa Fluor 488 donkey anti-rabbit IgG (Life Technologies). The sections were stained with 4=,6-
diamidino-2-phenylindole (DAPI) and mounted with an antifade mounting medium (Abcam, Cambridge, 
MA). Sections were analyzed by confocal microscopy (Zeiss LSM 700 confocal laser scanning microscope).
Inhibitors and treatment. Bromodomain inhibitor I-BET151 was obtained from GlaxoSmithKline 
(Research Triangle Park, NC). Drug powder was dissolved in 0.5% hydroxypropyl methylcellulose (HPMC)–
0.1% Tween 80 to a final concentration of 1.5 mg/ml and pH 5. Administration of the drug was through 
daily oral gavage at a dose of 18 mg/kg. The solvent without drug was used as a placebo. Highly potent 
and specific inhibitors of CDK2 (K03861) and CDK9 (LDC000067) (Selleckchem) were dissolved in DMSO 
and diluted to the desired concentration in medium before use.
Cell lines and culture. Jurkat and U-937 cells were obtained through the National Institutes of 
Health (NIH) AIDS Research and Reference Reagent Program, Division of AIDS. Cells were grown in RPMI 
1640 (Gibco) with 10% fetal bovine serum (FBS; Invitrogen), 5% penicillin-streptomycin (Invitrogen), and 
2 mM glutamine (Invitrogen). Cells were maintained at a concentration of 106/ml in T-175 flasks. Cell 
concentrations and cell viability were monitored throughout the experiment at all time points studied.
Primary cell isolation. Human blood buffy coats were ordered from Gulf Coast Regional Blood 
Center, and peripheral blood mononuclear cells (PBMCs) were separated with Ficoll (Ficoll-Paque Plus; GE 
Healthcare). Resting CD4 T cells were purified by negative selection using a CD4 separation kit (Miltenyi 
Biotec) according to the manufacturer’s instructions. CD25 CD4 T cells were subsequently isolated 
from CD4 T cells by negative selection using CD25 beads (Miltenyi Biotec). CD14 CD16 monocytes 
were isolated using the EasySep human monocyte isolation kit (STEMCELL). All cell purifications were 
performed according to the manufacturers’ instructions. The purity of CD25 CD4 T cells was checked 
by staining with anti-CD4-FITC and anti-CD25-PE (Biolegend). The purity of monocytes was checked by 
staining with anti-CD3-FITC and anti-CD14-PE (Biolegend). Cell purity was analyzed by Guava Easycyte 
8HT (EMD Millipore). The purity of each isolated population was over 90% (data not shown).
Primary cell transduction and culture. CD4 T cells were transduced with VSV-G Duo-Fluo reporter
virus at a multiplicity of infection (MOI) of 0.1 and cultured in RPMI 1640 complemented with 10% FBS
and interleukin 2 (IL-2) (10 U/ml) for 24 h before I-BET151 treatment. Monocyte-derived macrophages
(MDMs) were obtained by culturing monocytes with macrophage colony-stimulating factor (M-CSF;
50 ng/ml) and granulocyte-macrophage colony-stimulating factor (GM-CSF; 50 ng/ml) in RPMI 1640 with
10% FBS for 7 days. MDMs were harvested and transduced with VSV-G Duo-Fluo reporter virus at an MOI
of 0.1 and cultured for 24 h before I-BET151 treatment.
In vitro activation of HIV in cell lines. Cells were transduced with VSV-G HIV-luc, in which luciferase
gene expression is under the control of the HIV LTR, at an MOI of 1. After culture for 6 days, cells were
treated with the CDK2 inhibitor (K03861, 1 M) (1) or CDK9 inhibitor (LDC000067, 25 M) (Selleck
Chemicals) alone or in the presence of I-BET151. At 48 h after treatment, cells were washed with PBS and
lysed in 100 l of passive lysis buffer (Promega). Cell lysates were transferred into 96-well plates, and
luciferase activity was detected by adding 50 l of substrate into each well and read with a GloMax 96
microplate luminometer.
Statistical analysis. Unpaired 2-tailed t test was applied for in vivo experiment with three samples
in each group or in vitro assay with triplicates in each group. Mann-Whitney test was applied for all other
analyses. All comparisons were performed using GraphPad Prism (GraphPad Software, San Diego, CA). A
P value of 0.05 was considered statistically significant. All data were reported as means  standard
deviations (SD).
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